Apellis Pharmaceuticals (APLS)

• Market cap: $3.53B
• 1 day: -1.61%
• 5 days: 0.81%
• 1 month: 40.48%
• 3 months: 62.94%
• 6 months: 2.30%
• Year to date: -17.01%
• 1 year: -30.92%
• 5 years: -4.81%
• 10 years: 96.15%
• Sector: Healthcare
• Industry: Biotechnology

About: Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Employees: 710

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

386% more call options, than puts

Call options by funds: $47.3M | Put options by funds: $9.73M

54% more repeat investments, than reductions

Existing positions increased: 105 | Existing positions reduced: 68

3.29% more ownership

Funds ownership: 100.75% [Q1] → 104.04% (+3.29%) [Q2]

5% less funds holding

Funds holding: 254 [Q1] → 242 (-12) [Q2]

12% less first-time investments, than exits

New positions opened: 43 | Existing positions closed: 49

18% less capital invested

Capital invested by funds: $2.77B [Q1] → $2.26B (-$503M) [Q2]

33% less funds holding in top 10

Funds holding in top 10: 6 [Q1] → 4 (-2) [Q2]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $19 31% downside
• Avg. target: $36 32% upside
• High target: $52 89% upside

9 analyst ratings

• positive: 5 56%
• neutral: 4 44%
• negative: 0 0%

JP Morgan Anupam Rama	34% upside $37	Overweight Maintained	4 Aug 2025
Citigroup Yigal Nochomovitz	89% upside $52	Buy Maintained	1 Aug 2025
RBC Capital Lisa Walter	31% downside $19	Sector Perform Maintained	1 Aug 2025
Cantor Fitzgerald Steve Seedhouse	45% upside $40	Overweight Maintained	1 Aug 2025
Raymond James Ryan Deschner	82% upside $50	Outperform Maintained	1 Aug 2025